Can PDUFA V solve biopharma's R&D productivity crisis?
This article was originally published in Scrip
Executive Summary
There is a certain irony that the one issue that is actually garnering broad bipartisan support on Capitol Hill this year – user fees – is something that involves the US FDA, a "regulatory agency that, frankly, has not been the focus of a lot of affection over many years from Congress and others," said a beaming FDA Commissioner Dr Margaret Hamburg.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.